Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights

作者：Chen, Wenshuo; Chen, Haijin^*; Fu, Shudan; Lin, Xiaohua; Zheng, Zheng; Zhang, Jinlong

来源：Bioprocess and Biosystems Engineering, 2021, 44(5): 929-939.

DOI：10.1007/s00449-020-02380-y

• Inflammatory bowel disease
• Crohn's diseases
• Ulcerative colitis
• Biological agent

The therapeutic effect of inflammatory bowel disease has improved in the past decades, but most of patients cannot tolerate, do not respond to drugs, or relapse after treating with conventional therapy. Therefore, new and more effective treatment methods are still needed in treatment of IBD. In this review, we will discuss the relevant mechanisms and the latest research progress of biologics (anti-TNF treatments, interleukin inhibitors, integrin inhibitors, antisense oligonucleotide, and JAK inhibitors) for IBD, focus on the efficacy and safety of drugs for moderate-to-severe IBD, and summarize the clinical status and future development direction of biologics in IBD.

• 单位
  南方医科大学